Management and outcomes of hydronephrosis in patients with metastatic extramammary Paget’s disease: A retrospective analysis
Management and outcomes of hydronephrosis in patients with metastatic extramammary Paget’s disease: A retrospective analysis
复制标题
转移性乳房外佩吉特病患者肾积水的治疗和结局：回顾性分析
DOI：
10.1111/1346-8138.16407
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Funakoshi Takeru
中科院分区：
文献类型：
--
作者：
Fusumae Takayuki;Fukuda Keitaro;Hirai Ikuko;Nakamura Yoshio;Kobayashi Kenta;Tanese Keiji;Matsumoto Kazuhiro;Iwata Takashi;Funakoshi Takeru
医学实践中已观察到伴有远处转移（转移性 EMPD）的乳外佩吉特病（EMPD）出现肾积水；然而，其预后仍不清楚。进行回顾性分析以评估转移性 EMPD 肾积水的治疗和结果。在对 44 名转移性 EMPD 患者的随访中，13 名（30%）出现肾积水。 13例肾积水患者中有10例（77%）肾功能受损（估计肾小球滤过率：<60ml/min/1.73m2），每例肾功能受损的患者均放置输尿管支架。 10名患者支架均成功放置，肾功能在中位7天内恢复。重要的是，这些患者中的每一位都继续化疗，并且没有一个出现支架失败的情况。患有转移性 EMPD 和肾积水的患者 (n=13) 的中位总生存时间 (OS) 为 7.8 个月。肾积水治疗并不是 OS 的重要因素，接受输尿管支架置换术的患者 (n = 10) 的中位 OS 为 14.7 个月。总的来说，我们的结果表明肾积水相对常见，对于转移性EMPD伴肾积水的病例应考虑放置输尿管支架，以维持肾功能并继续化疗以获得更好的预后。
Hydronephrosis in extramammary Paget’s disease (EMPD) with distant metastasis (metastatic EMPD) has been observed in medical practice; however, its prognosis remains unclear. Retrospective analyses were performed to assess the management and outcomes of hydronephrosis in metastatic EMPD. During a follow‐up of 44 patients with metastatic EMPD, 13 (30%) developed hydronephrosis. Ten (77%) of the 13 patients with hydronephrosis had impaired renal function (estimated glomerular filtration rate: <60 ml/min/1.73 m2), and ureteral stents were placed in every patient with impaired renal function. The stent was placed successfully in all 10 patients, and their renal function recovered within a median period of 7 days. Importantly, each of these patients continued chemotherapy, and none of them experienced stent failure. The median overall survival time (OS) in patients with metastatic EMPD and hydronephrosis (n= 13) was 7.8 months. Treatment for hydronephrosis was not a significant factor for OS, and median OS in patients who underwent ureteral stent replacement (n= 10) was 14.7 months. Collectively, our results indicate that hydronephrosis is relatively common, and ureteral stent placement should be considered in cases of metastatic EMPD with hydronephrosis to maintain renal function and continue chemotherapy toward a better prognosis.
影响因子：
4.6
作者：
Izumi K;Shima T;Shigehara K;Sawada K;Naito R;Kato Y;Ofude M;Kano H;Iwamoto H;Yaegashi H;Nakashima K;Iijima M;Kawaguchi S;Nohara T;Kadono Y;Mizokami A
通讯作者：
Mizokami A
影响因子：
2.6
作者：
Kamiyama, Yoshihiro;Matsuura, Shinobu;Arai, Yoichi
通讯作者：
Arai, Yoichi
影响因子：
3.3
作者：
Matsuura, Hiroshi;Arase, Shigeki;Hori, Yasuhide
通讯作者：
Hori, Yasuhide